Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 19809159)

1.

Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.

Taylor JG 6th, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, Fang J, Kim SY, Yeung C, Helman LJ, Mendoza A, Ngo V, Staudt LM, Wei JS, Khanna C, Catchpoole D, Qualman SJ, Hewitt SM, Merlino G, Chanock SJ, Khan J.

J Clin Invest. 2009 Nov;119(11):3395-407. doi: 10.1172/JCI39703. Epub 2009 Oct 5.

2.

Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).

Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS, Khan J.

PLoS One. 2013 Oct 4;8(10):e76551. doi: 10.1371/journal.pone.0076551. eCollection 2013.

3.

FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, Linardic CM.

Clin Cancer Res. 2012 Jul 15;18(14):3780-90. doi: 10.1158/1078-0432.CCR-10-3063. Epub 2012 May 30.

4.

The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells.

Roidl A, Foo P, Wong W, Mann C, Bechtold S, Berger HJ, Streit S, Ruhe JE, Hart S, Ullrich A, Ho HK.

Oncogene. 2010 Mar 11;29(10):1543-52. doi: 10.1038/onc.2009.432. Epub 2009 Nov 30.

PMID:
19946327
5.

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R.

Cancer Res. 2003 Oct 1;63(19):6272-81.

6.
7.

PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.

Marshall AD, van der Ent MA, Grosveld GC.

Mol Carcinog. 2012 Oct;51(10):807-15. doi: 10.1002/mc.20848. Epub 2011 Aug 31.

PMID:
21882254
8.
9.

Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion.

Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG, Lisanti MP.

J Biol Chem. 2004 Dec 3;279(49):51630-46. Epub 2004 Sep 7.

10.

Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.

Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE.

Cancer Res. 2010 May 15;70(10):4151-62. doi: 10.1158/0008-5472.CAN-09-4479. Epub 2010 May 11.

11.

FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.

Peláez-García A, Barderas R, Torres S, Hernández-Varas P, Teixidó J, Bonilla F, de Herreros AG, Casal JI.

PLoS One. 2013 May 16;8(5):e63695. doi: 10.1371/journal.pone.0063695. Print 2013.

12.

Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.

Peace BE, Hughes MJ, Degen SJ, Waltz SE.

Oncogene. 2001 Sep 27;20(43):6142-51.

13.

Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.

Turkington RC, Longley DB, Allen WL, Stevenson L, McLaughlin K, Dunne PD, Blayney JK, Salto-Tellez M, Van Schaeybroeck S, Johnston PG.

Cell Death Dis. 2014 Feb 6;5:e1046. doi: 10.1038/cddis.2014.10.

14.
15.

A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer.

Delfino FJ, Stevenson H, Smithgall TE.

J Biol Chem. 2006 Mar 31;281(13):8829-35. Epub 2006 Feb 2.

16.

CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion.

Libura J, Drukala J, Majka M, Tomescu O, Navenot JM, Kucia M, Marquez L, Peiper SC, Barr FG, Janowska-Wieczorek A, Ratajczak MZ.

Blood. 2002 Oct 1;100(7):2597-606.

17.

Methionine dependency of malignant tumors: a possible approach for therapy.

Breillout F, Antoine E, Poupon MF.

J Natl Cancer Inst. 1990 Oct 17;82(20):1628-32.

PMID:
2213904
18.

Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling.

Lukasiewicz E, Miekus K, Kijowski J, Drabik G, Wilusz M, Bobis-Wozowicz S, Majka M.

Folia Histochem Cytobiol. 2009 Jan;47(3):485-9. doi: 10.2478/v10042-009-0108-x.

19.

Generation and characterization of a panel of monoclonal antibodies specific for human fibroblast growth factor receptor 4 (FGFR4).

Chen C, Patel S, Corisdeo S, Liu X, Micolochick H, Xue J, Yang Q, Lei Y, Wang B, Soltis D.

Hybridoma (Larchmt). 2005 Jun;24(3):152-9.

PMID:
15943563
20.

Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.

Ezzat S, Zheng L, Winer D, Asa SL.

Mol Endocrinol. 2006 Nov;20(11):2965-75. Epub 2006 Jul 20.

PMID:
16857743
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk